Hypoglycemia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hypoglycemia – Pipeline Review, H2 2017’, provides an overview of the Hypoglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypoglycemia

The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects

The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypoglycemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypoglycemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adocia SAS

Arecor Ltd

Eiger BioPharmaceuticals Inc

Eli Lilly and Company

Heptares Therapeutics Ltd

LATITUDE Pharmaceuticals Inc

Novartis AG

Therakind Ltd

USV Pvt Ltd

Vectura Group Plc

XERIS Pharmaceuticals Inc

XOMA Corp

Zealand Pharma AS

Zucara Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hypoglycemia - Overview 6

Hypoglycemia - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 10

Hypoglycemia - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Hypoglycemia - Companies Involved in Therapeutics Development 20

Adocia SAS 20

Arecor Ltd 20

Eiger BioPharmaceuticals Inc 21

Eli Lilly and Company 21

Heptares Therapeutics Ltd 22

LATITUDE Pharmaceuticals Inc 22

Novartis AG 23

Therakind Ltd 23

USV Pvt Ltd 24

Vectura Group Plc 24

XERIS Pharmaceuticals Inc 25

XOMA Corp 25

Zealand Pharma AS 26

Zucara Therapeutics Inc 26

Hypoglycemia - Drug Profiles 27

(glucagon + GLP-1) - Drug Profile 27

(insulin human + pramlintide) - Drug Profile 28

dasiglucagon - Drug Profile 29

Drug for Hypoglycemia - Drug Profile 33

exendin-(9-39) - Drug Profile 34

glucagon - Drug Profile 37

glucagon - Drug Profile 41

glucagon - Drug Profile 42

glucagon - Drug Profile 43

glucagon biosimilar - Drug Profile 44

LY-3143753 - Drug Profile 45

LY-3185643 - Drug Profile 46

LY-900018 - Drug Profile 47

pasireotide - Drug Profile 49

PRL-2903 - Drug Profile 53

Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile 54

Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile 55

Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile 56

terbutaline sulphate MR - Drug Profile 57

XOMA-129 - Drug Profile 58

XOMA-358 - Drug Profile 59

Hypoglycemia - Dormant Projects 62

Hypoglycemia - Discontinued Products 63

Hypoglycemia - Product Development Milestones 64

Featured News & Press Releases 64

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Tables

List of Tables

Number of Products under Development for Hypoglycemia, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Hypoglycemia – Pipeline by Adocia SAS, H2 2017

Hypoglycemia – Pipeline by Arecor Ltd, H2 2017

Hypoglycemia – Pipeline by Eiger BioPharmaceuticals Inc, H2 2017

Hypoglycemia – Pipeline by Eli Lilly and Company, H2 2017

Hypoglycemia – Pipeline by Heptares Therapeutics Ltd, H2 2017

Hypoglycemia – Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017

Hypoglycemia – Pipeline by Novartis AG, H2 2017

Hypoglycemia – Pipeline by Therakind Ltd, H2 2017

Hypoglycemia – Pipeline by USV Pvt Ltd, H2 2017

Hypoglycemia – Pipeline by Vectura Group Plc, H2 2017

Hypoglycemia – Pipeline by XERIS Pharmaceuticals Inc, H2 2017

Hypoglycemia – Pipeline by XOMA Corp, H2 2017

Hypoglycemia – Pipeline by Zealand Pharma AS, H2 2017

Hypoglycemia – Pipeline by Zucara Therapeutics Inc, H2 2017

Hypoglycemia – Dormant Projects, H2 2017

Hypoglycemia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Hypoglycemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports